Clarivate: PE Rollup Down 85% Generates $365M FCF at 30% Yield With 93% Renewal Rates
Mission-critical data franchises or permanently broken rollup? Six lenses examined the gap between market narrative and operational reality.
30% yield at current market cap
Up 100bps YoY, highest in years
Down from ~5x, targeting further reduction
From ~$30 post-acquisition highs
Clarivate PLC is one of the most polarizing names in information services. The company owns some of the most established data franchises in the world: Web of Science (the premier academic citation database, 60+ years of curated data), Derwent Innovation (patent analytics), and CPA Global (the largest patent annuity book globally). These assets serve 45,000+ institutions and generate $365M in free cash flow with 93% renewal rates.
Yet the stock has lost 85% of its value from post-acquisition highs. The PE-era acquisition strategy (CPA Global for $6.8B, ProQuest for $5.3B within 12 months) loaded the balance sheet with $4.7B in debt and created massive goodwill that has since been impaired. Three CEO transitions in five years compounded the instability. The market consensus is straightforward: broken rollup with AI disruption risk.
We ran six lenses to examine whether the market narrative matches the operational reality. The answer is more nuanced than either the bulls or bears acknowledge.
Want the full 6-lens analysis with signal assessments and model debates?
Opus + Sonnet ensemble. 6 lenses. 9 signals. 6 debates. Full evidence citations.
Signal Assessments
Adj. EBITDA >$1B vs. GAAP net income $3M in Q4. $55M+ restructuring classified as one-time. First time meeting guidance since 2019.
3+ CEO transitions since IPO. Current CEO has deep domain expertise. All insiders net accumulators via RSU grants.
4x net leverage on flat organic revenue. No near-term maturities. $365M FCF covers debt service. LS&H sale is key catalyst.
$12B in PE acquisitions created 85% stock decline. Goodwill impairments confirm overpayment. Portfolio rationalization underway.
60-year curated datasets and largest patent annuity book are real moats. AI threatens discovery layer but reinforces compliance workflows.
Market prices permanent impairment. Operations show stabilization: ACV accelerating, renewals improving, FCF growing.
30% FCF yield implies significant deterioration ahead. If FY2026 guidance is met ($400M FCF), the stock appears mispriced.
88% recurring mix, 93% renewals. Organic growth flat. ACV accelerating to 2%. IP return to growth is the swing factor.
No enforcement actions. Open access mandates theoretical. Patent fee changes early stage. New Jersey corporate tax.
Key Findings
PE Rollup Destroyed Shareholder Value -- The Numbers Are Stark
CPA Global ($6.8B) and ProQuest ($5.3B) were acquired within 12 months, loading $12B of acquisition cost onto a $2.5B revenue business. The resulting leverage, integration complexity, and management bandwidth drain led to years of missed guidance. Goodwill impairments of hundreds of millions confirm the assets were overvalued. The stock lost 85%.
The Moats Are Real -- Web of Science and CPA Global Are Defensible Franchises
Web of Science has 60+ years of curated citation data used by 45,000+ institutions globally. The patent annuity business is the world's largest, compliance-driven, and benefits from a structural tailwind (AI patent filings grew 5x from pre-ChatGPT levels). Renewal rates of 93%, up 100bps year-over-year, demonstrate that customers are not defecting despite the AI disruption narrative. The 97% proprietary revenue figure is genuine.
AI Is Both Threat and Opportunity -- The Market Does Not Distinguish
The market treats AI as a blanket existential risk for database companies. The reality is more layered. AI commoditizes the discovery layer (finding research), where free alternatives like OpenAlex and Semantic Scholar are growing. But it reinforces the compliance/workflow layer (patent prosecution, FDA intelligence, research evaluation), where provenance and accuracy are non-negotiable. Clarivate's Nexus strategy embeds Web of Science into public AI tools, turning disruption into distribution.
Where Models Disagreed
Does AI Strengthen or Weaken the Moat?
Opus Position
AI fundamentally commoditizes the discovery layer. Researchers can use general-purpose AI to find papers, making Web of Science less essential. The moat narrows to curation and trust alone, which is a smaller defensible perimeter.
Sonnet Position
In high-stakes workflows (FDA compliance, patent prosecution, university funding allocation), provenance and accuracy are non-negotiable. General-purpose AI lacks the governance layer that institutional customers require. AI amplifies the value of curated, trusted data.
This debate persisted through 4 rounds and required forced convergence at CONDITIONAL. The analytical disagreement cannot be resolved because the outcome depends on technological evolution over 3-5 years.
Is the 30% FCF Yield a Value Trap or Genuine Mispricing?
Mispricing Argument
$365M FCF is real cash (not adjusted). Debt is serviceable with no near-term maturities. The LS&H sale provides a catalyst. If the company merely executes 2026 guidance, current pricing implies significant deterioration that operational data does not support.
Value Trap Argument
High FCF yields on leveraged, flat-growth companies are classic value traps. The market correctly prices in execution risk (years of missed guidance), potential FCF deterioration from AI competition, and the possibility that management pursues further acquisitions rather than deleveraging.
Converged on BELOW_CONSENSUS -- the stock is more likely mispriced than trapped, but confirmation requires 2-3 quarters of organic growth delivery and the LS&H sale outcome.
Cross-Lens Reinforcements
All six lenses agree: PE acquisitions destroyed value, current direction is correct
The Consolidation Calibrator, Fugazi Filter, and Stress Scanner all identify the same root cause (overleveraged acquisitions) from different angles. All also recognize that portfolio rationalization is the right corrective strategy.
Revenue base is durable but growth remains unproven
The Gravy Gauge, Moat Mapper, and Myth Meter converge on: 93% renewal rates prove current stickiness, but organic revenue is flat. ACV acceleration is encouraging but has not yet translated to revenue growth.
Market prices in worse outcomes than operational data supports
The Myth Meter, Stress Scanner, and Gravy Gauge all find that the 30% FCF yield implies significant deterioration ahead. Operational metrics (improving ACV, stable renewals, growing FCF) do not yet confirm this deterioration.
What to Watch
Active discussions underway. If completed at reasonable valuation, shifts leverage from ~4x toward sub-3.5x and validates the portfolio simplification strategy. If failed, the turnaround timeline extends by 2+ years and the bull thesis weakens materially.
Currently flat. FY2026 guidance is 1-2%. Positive growth for 2+ consecutive quarters would confirm the turnaround and shift the Gravy Gauge assessment toward DURABLE. This is the single most important operational metric.
Currently near flat. This ~$800M business is the largest drag on company-wide metrics. Return to growth (aided by AI patent filing tailwinds and new leadership) would transform the growth profile. Patent annuities have a 2-3 year lag from filing surge.
Currently 93%. Any decline below 91% would indicate that AI disruption or university budget pressure is becoming material and would weaken the competitive moat assessment.
HIGHER SCRUTINY
Clarivate is a damaged but stabilizing franchise with genuine moats under pressure. The PE-era acquisitions destroyed value, but the underlying data assets continue to generate substantial cash flow with high retention. Current management is pursuing the correct strategy with portfolio rationalization and AI investment. The 30% FCF yield creates potential asymmetry, but the company's multi-year track record of missed guidance demands proof before a more favorable assessment.
Path to More Favorable Assessment
- • LS&H sale at reasonable valuation (reduces leverage below 3.5x)
- • 2+ quarters of organic recurring revenue growth above 1%
- • IP segment return to positive ACV growth
- • Continued renewal rate stability at 92%+
- • One-time costs declining as guided for FY2026
Path to Less Favorable Assessment
- • LS&H sale fails or produces below-expectations proceeds
- • Organic revenue turns negative again
- • Renewal rates decline below 91%
- • Additional goodwill impairment charges
- • Management returns to acquisition mode before de-leveraging
This analysis is for educational purposes only -- it is not a recommendation to buy or sell any security.
Public Sources Used (13 documents)
- Annual Report (10-K) -- FY2025
- Quarterly Reports (10-Q) -- Q1-Q3 2025, Q3 2024
- Current Reports (8-K) -- 10 filings (2025-2026)
- Q4 2025 Earnings Call Transcript
- Q3 2025 Earnings Call Transcript
- Q2 2025 Earnings Call Transcript
- Q1 2025 Earnings Call Transcript
- Form 4 Insider Transactions (20 filings)
- Form 144 Proposed Insider Sales (5 filings)
- CourtListener Litigation Search -- courtlistener.com
Full Analysis with Signal Breakdowns
Explore the complete 6-lens assessment including debate transcripts, evidence citations, visualization dashboards, and monitoring triggers for Clarivate.
View CLVT Analysis